← Back to Search

Transcranial Magnetic Stimulation

Deep TMS for Stimulant Use Disorder (SUDdTMS Trial)

Waitlist Available
Led By Jean-Philippe Miron, MD
Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Being voluntary and competent to consent to treatment
Ability to speak and read French or English
Screening 3 weeks
Treatment Varies
Follow Up up to three months after end of the treatment
Awards & highlights

SUDdTMS Trial Summary

This trialwill test a new treatment for people struggling with substance use disorder: a magnetic coil placed on the head.

Who is the study for?
This trial is for adults who have been diagnosed with moderate or severe Stimulant Use Disorder, are currently using stimulants, and want to quit. They must be able to understand French or English, consent to treatment, and follow the schedule. People with severe medical conditions, unstable medication use, significant sensory impairments, other metal implants in their body (except dental), pregnant or breastfeeding women, and those with certain psychiatric conditions cannot participate.Check my eligibility
What is being tested?
The study is testing the feasibility and safety of a technique called H7-Coil deep Transcranial Magnetic Stimulation (TMS) as a potential treatment for people struggling with Stimulant Use Disorder. Participants will undergo sessions where magnetic fields stimulate brain regions involved in addiction.See study design
What are the potential side effects?
Potential side effects of deep TMS may include discomfort at the stimulation site on the scalp, headache during or after treatment, lightheadedness, twitching of facial muscles during stimulation sessions and rare risk of seizure.

SUDdTMS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am willing and able to agree to treatment.
I can speak and read either French or English.

SUDdTMS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to three months after end of the treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to three months after end of the treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse Events reported
Feasibility-related endpoints - adherence to dTMS
Feasibility-related endpoints - retention rates
Secondary outcome measures
Percentage change on General Anxiety Disorder (GAD-7)
Percentage change on Patient Health Questionnaire (PHQ-9)
Percentage change on Stimulants Craving Questionnaire
+2 more

SUDdTMS Trial Design

1Treatment groups
Experimental Treatment
Group I: H7-Coil Deep TMS TreatmentExperimental Treatment1 Intervention
H7-Coil Deep TMS Treatment

Find a Location

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor
366 Previous Clinical Trials
129,622 Total Patients Enrolled
Jean-Philippe Miron, MDPrincipal InvestigatorCentre hospitalier de l'Université de Montréal (CHUM)
1 Previous Clinical Trials
30 Total Patients Enrolled

Media Library

H7-Coil (Transcranial Magnetic Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT05274828 — N/A
Stimulant Use Disorder Research Study Groups: H7-Coil Deep TMS Treatment
Stimulant Use Disorder Clinical Trial 2023: H7-Coil Highlights & Side Effects. Trial Name: NCT05274828 — N/A
H7-Coil (Transcranial Magnetic Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05274828 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Am I eligible to enlist in this clinical trial?

"This clinical trial is recruiting 30 people aged 21 to 65 with cocaine use disorders (SUD) based on DSM-5 criteria, recent stimulants intake in the two weeks preceding recruitment, and a desire to cease usage. Furthermore, candidates must display competency for consenting to treatment and pass an adult safety screening questionnaire; they must also be fluent in either English or French."

Answered by AI

Does the trial admit participants who are of legal age?

"This medical trial is designed for participants between the ages of 21 to 65. Those under 18 can find 248 studies, while those over 65 have 627 options available."

Answered by AI

What are the projected outcomes of this experiment?

"This trial is evaluating the feasibility of treatment by monitoring participant retention across a 10-day timeframe. Secondary results will be tracked with urine drug screening, Stimulants Selective Severity Assessment scores (ranging from 0–126), and Patient Health Questionnaire (PHQ-9) changes."

Answered by AI

Are there any remaining openings for people to participate in this investigation?

"According to the information found on clinicaltrials.gov, recruitment for this medical experiment has commenced and is ongoing. The trial was initially announced on November 2nd 2022 with the latest update being posted 9 days later."

Answered by AI

How many persons are actively participating in this experiment?

"Absolutely. Details on clinicaltrials.gov make mention that this experiment is presently seeking participants, with the first posting being made on November 2nd 2022 and last updated 9 days later. The trial will accept 30 patients from a single medical facility."

Answered by AI
~6 spots leftby Apr 2025